A Phase I/II Trial Testing Immunization With AFP + GM-CSF Plasmid Prime And AFP Adenoviral Vector Boost In Patients With ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

-

ABSTRACT

RATIONALE: Vaccines made from DNA and a gene-modified virus may make the body build an immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of liver cancer. PURPOSE: This phase I/II trial is studying the side effects and best dose of vaccine therapy and to see how well it works in treating patients with stage II, stage IIIA, stage IIIB, or stage IVA liver cancer. Detailed Description OBJECTIVES: Primary - Determine the dose-limiting toxicity and maximum tolerated dose of adjuvant vaccination comprising alpha fetoprotein (AFP) plasmid DNA and sargramostim (GM-CSF) plasmid DNA followed by AFP adenoviral vector boost in patients with HLA-A*0201-expressing stage II-IVA hepatocellular carcinoma. Secondary - Determine the optimal biological dose of this regimen, as defined by the generation of AFP-specific immunity, in these patients. - Determine disease-free survival of patients treated with this regimen. OUTLINE: This is a dose-escalation study of alpha fetoprotein (AFP) adenoviral vector boost. Patients receive vaccination comprising AFP plasmid DNA and sargramostim (GM-CSF) plasmid DNA intramuscularly (IM) on days 1, 30, and 60 in the absence of unacceptable toxicity. Patients then receive boost immunization comprising AFP adenoviral vector IM and intradermally on day 90. Cohorts of 3-6 patients receive escalating doses of AFP adenoviral vector boost until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients are followed monthly for 3 months and then every 6 months thereafter. PROJECTED ACCRUAL: A total of 3-25 patients will be accrued for this study. More... »

URL

https://clinicaltrials.gov/show/NCT00093548

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "RATIONALE: Vaccines made from DNA and a gene-modified virus may make the body build an immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of liver cancer. PURPOSE: This phase I/II trial is studying the side effects and best dose of vaccine therapy and to see how well it works in treating patients with stage II, stage IIIA, stage IIIB, or stage IVA liver cancer.\n\nDetailed Description\nOBJECTIVES: Primary - Determine the dose-limiting toxicity and maximum tolerated dose of adjuvant vaccination comprising alpha fetoprotein (AFP) plasmid DNA and sargramostim (GM-CSF) plasmid DNA followed by AFP adenoviral vector boost in patients with HLA-A*0201-expressing stage II-IVA hepatocellular carcinoma. Secondary - Determine the optimal biological dose of this regimen, as defined by the generation of AFP-specific immunity, in these patients. - Determine disease-free survival of patients treated with this regimen. OUTLINE: This is a dose-escalation study of alpha fetoprotein (AFP) adenoviral vector boost. Patients receive vaccination comprising AFP plasmid DNA and sargramostim (GM-CSF) plasmid DNA intramuscularly (IM) on days 1, 30, and 60 in the absence of unacceptable toxicity. Patients then receive boost immunization comprising AFP adenoviral vector IM and intradermally on day 90. Cohorts of 3-6 patients receive escalating doses of AFP adenoviral vector boost until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients are followed monthly for 3 months and then every 6 months thereafter. PROJECTED ACCRUAL: A total of 3-25 patients will be accrued for this study.", 
    "id": "sg:clinicaltrial.NCT00093548", 
    "keywords": [
      "phase I/II trial", 
      "AFP", 
      "plasmid", 
      "adenoviral vector", 
      "hepatocellular carcinoma", 
      "protocol", 
      "rationale", 
      "vaccine", 
      "DNA", 
      "modified virus", 
      "body", 
      "immune response", 
      "tumor cell", 
      "booster vaccination", 
      "strong immune response", 
      "delay", 
      "Recurrence", 
      "Liver Neoplasm", 
      "side effect", 
      "dose", 
      "active immunotherapy", 
      "patient", 
      "Stage II", 
      "stage", 
      "Determine", 
      "dose-limiting toxicity", 
      "maximum tolerated dose", 
      "plasmid DNA", 
      "Granulocyte-Macrophage Colony-Stimulating Factor", 
      "regimen", 
      "generation", 
      "specific immunity", 
      "Disease-Free Survival", 
      "dose escalation study", 
      "vaccination", 
      "IM", 
      "absence", 
      "toxicity", 
      "immunization", 
      "cohort", 
      "accrual"
    ], 
    "name": "A Phase I/II Trial Testing Immunization With AFP + GM-CSF Plasmid Prime And AFP Adenoviral Vector Boost In Patients With Hepatocellular Carcinoma (AFP Prime-Boost Protocol)", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT00093548"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:21", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00001.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.48336.3a", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.19006.3e", 
        "type": "Organization"
      }
    ], 
    "subjectOf": [
      {
        "id": "sg:pub.10.1186/1479-5876-12-86", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005372522", 
          "https://doi.org/10.1186/1479-5876-12-86"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT00093548"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00093548'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00093548'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00093548'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00093548'


 

This table displays all metadata directly associated to this object as RDF triples.

64 TRIPLES      14 PREDICATES      56 URIs      48 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT00093548 schema:about anzsrc-for:3103
2 schema:description RATIONALE: Vaccines made from DNA and a gene-modified virus may make the body build an immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of liver cancer. PURPOSE: This phase I/II trial is studying the side effects and best dose of vaccine therapy and to see how well it works in treating patients with stage II, stage IIIA, stage IIIB, or stage IVA liver cancer. Detailed Description OBJECTIVES: Primary - Determine the dose-limiting toxicity and maximum tolerated dose of adjuvant vaccination comprising alpha fetoprotein (AFP) plasmid DNA and sargramostim (GM-CSF) plasmid DNA followed by AFP adenoviral vector boost in patients with HLA-A*0201-expressing stage II-IVA hepatocellular carcinoma. Secondary - Determine the optimal biological dose of this regimen, as defined by the generation of AFP-specific immunity, in these patients. - Determine disease-free survival of patients treated with this regimen. OUTLINE: This is a dose-escalation study of alpha fetoprotein (AFP) adenoviral vector boost. Patients receive vaccination comprising AFP plasmid DNA and sargramostim (GM-CSF) plasmid DNA intramuscularly (IM) on days 1, 30, and 60 in the absence of unacceptable toxicity. Patients then receive boost immunization comprising AFP adenoviral vector IM and intradermally on day 90. Cohorts of 3-6 patients receive escalating doses of AFP adenoviral vector boost until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Patients are followed monthly for 3 months and then every 6 months thereafter. PROJECTED ACCRUAL: A total of 3-25 patients will be accrued for this study.
3 schema:keywords AFP
4 DNA
5 Determine
6 Disease-Free Survival
7 Granulocyte-Macrophage Colony-Stimulating Factor
8 IM
9 Liver Neoplasm
10 Recurrence
11 Stage II
12 absence
13 accrual
14 active immunotherapy
15 adenoviral vector
16 body
17 booster vaccination
18 cohort
19 delay
20 dose
21 dose escalation study
22 dose-limiting toxicity
23 generation
24 hepatocellular carcinoma
25 immune response
26 immunization
27 maximum tolerated dose
28 modified virus
29 patient
30 phase I/II trial
31 plasmid
32 plasmid DNA
33 protocol
34 rationale
35 regimen
36 side effect
37 specific immunity
38 stage
39 strong immune response
40 toxicity
41 tumor cell
42 vaccination
43 vaccine
44 schema:name A Phase I/II Trial Testing Immunization With AFP + GM-CSF Plasmid Prime And AFP Adenoviral Vector Boost In Patients With Hepatocellular Carcinoma (AFP Prime-Boost Protocol)
45 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00093548
46 schema:sdDatePublished 2019-03-07T15:21
47 schema:sdLicense https://scigraph.springernature.com/explorer/license/
48 schema:sdPublisher Nd1644d951c0f47d7a09ce1035b214500
49 schema:sponsor https://www.grid.ac/institutes/grid.19006.3e
50 https://www.grid.ac/institutes/grid.48336.3a
51 schema:subjectOf sg:pub.10.1186/1479-5876-12-86
52 schema:url https://clinicaltrials.gov/show/NCT00093548
53 sgo:license sg:explorer/license/
54 sgo:sdDataset clinical_trials
55 rdf:type schema:MedicalStudy
56 Nd1644d951c0f47d7a09ce1035b214500 schema:name Springer Nature - SN SciGraph project
57 rdf:type schema:Organization
58 anzsrc-for:3103 schema:inDefinedTermSet anzsrc-for:
59 rdf:type schema:DefinedTerm
60 sg:pub.10.1186/1479-5876-12-86 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005372522
61 https://doi.org/10.1186/1479-5876-12-86
62 rdf:type schema:CreativeWork
63 https://www.grid.ac/institutes/grid.19006.3e schema:Organization
64 https://www.grid.ac/institutes/grid.48336.3a schema:Organization
 




Preview window. Press ESC to close (or click here)


...